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Abstract
Background: Lifestyle interventions, including increase in physical activity and dietary counselling, have shown
the ability to prevent type 2 diabetes (T2D) in high-risk state individuals, but the prevalence is still skyrocketing
in Australia, in line with global prevalence. Currently, no medicines are approved by the Therapeutic Goods
Administration in Australia for the management of prediabetes. Therefore, there is a need of developing a safer,
biologically efficacious and cost-effective alternative for delaying the transition of individual health state from
prediabetes into T2D. In the current trial we propose to evaluate the effects of curcumin and/or long-chain
omega-3 polyunsaturated fatty acids on improving glycosylated haemoglobin as a primary outcome, along with
secondary outcomes of glycaemic indices, lipid profile and inflammatory parameters.
Methods/design: Eighty individuals diagnosed with prediabetes, aged between 30 and 70 years, will be randomly
assigned to double placebo, curcumin alone, fish oil alone or double active groups according to a computer-
generated randomisation sequence for 12 weeks. At baseline and post-intervention visits participants will be
asked to provide blood samples and undergo body composition measurements. A blood sample is used for
estimating glycaemic profiles, lipid profiles and inflammatory parameters (C-reactive protein, whole blood cell
count, adiponectin, leptin, interleukin-6). The interim visit includes review on compliance with supplements
based on capsule log and capsule count, adverse events and anthropometric measurements. In addition to
these procedures, participants provide self-reported questionnaires on dietary intake (using a 3-day food record),
a physical activity questionnaire and medical history.
Discussion: This trial aims to determine whether curcumin and/or long-chain omega-3 polyunsaturated fatty acids
affect surrogate markers of glycaemic control which is relevant to delaying T2D. To date 38 participants completed
the trial. No changes have been made to the clinical protocol post recruitment. If successful, this trial will provide
considerable evidence for performing a larger trial to investigate whether this combination can be administered
for preventing or delaying the onset of T2D in high-risk individuals.
Trial registration: ACTRN12615000559516, registered on 29 May 2015).
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Background
Type 2 diabetes (T2D) is a chronic and noncommunic-
able metabolic disorder characterised by hyperglycaemia
resulting from defective secretion and/or action of insu-
lin. The prevalence of T2D has been increasing rapidly
worldwide at an alarming rate due to over nutrition,
physical inactivity, urbanisation (especially in developing
countries) and genetic predisposition [1–4]. People with
prediabetes, who are at a high risk of developing T2D,
have intermediate glucose levels that are elevated but
not high enough to be diagnosed as T2D. They are
classed as having either impaired glucose tolerance
(IGT), impaired fasting glucose (IFG) or both. In 2015,
over 318 million people were living with prediabetes
worldwide, and this number is expected to rise to 471
million by 2035 [5]. Five to ten percent of the individuals
diagnosed with prediabetes continue to progress to overt
T2D annually [6]. Despite its complex and heteroge-
neous nature, T2D often coexists with obesity, hyperten-
sion and dyslipidaemia which are also common features
of ageing [7–10]. Recent advances in molecular biology
have provided in-depth understanding of the mecha-
nisms that are involved in the pathobiology of T2D
highlighting the role of glucotoxicity, lipotoxicity, oxida-
tive stress and endoplasmic reticulum stress [11–13]. An
elevated level of subclinical inflammation for prolonged
periods is believed to be the primary trigger preceding
all of the above mechanisms [14]. These pathological
mechanisms mediate a reduction in insulin-stimulated
glucose uptake leading to insulin resistance. Insulin re-
sistance, present throughout the prediabetic stage, acts
as a conduit between the progression of the subclinical
inflammatory state to T2D.
The presence of insulin resistance in prediabetes also
modulates the risk of developing T2D, and individuals
with combined IGT and IFG are at greater risk of devel-
oping T2D than those with IFG or IGT alone [6, 15]. In-
sulin resistance is prevalent in both the cases, but people
with IFG have more hepatic insulin resistance and those
with IGT have more skeletal muscle resistance with less
effect on hepatic insulin sensitivity [16, 17]. Along with
insulin resistance, beta-cell dysfunction is present in
both IFG and IGT individuals. However, they differ in
time of insulin secretion response during an oral glucose
tolerance test (OGTT). Individuals with IGT have both
impaired early and late insulin response, in contrast to
IFG individuals where only early phase insulin response
is impaired [16]. These observations indicate that insulin
resistance and moderate beta-cell dysfunction is already
present in individuals with IFG and IGT (prediabetes).
Diabetes prevention studies have found that lifestyle
interventions aiming at weight reduction through dietary
intake changes and increase in physical activity signifi-
cantly reduce the risk of developing T2D [15, 18].
Lifestyle interventions resulting in weight loss also im-
proved insulin sensitivity and beta-cell function [19–21].
However, maintaining weight loss and physical activity is
very difficult over longer periods of time. Lack of com-
pliance with these interventions is a barrier for effective-
ness in halting the progression to T2D in high-risk
individuals, indicating that dietary and lifestyle modifica-
tions alone are insufficient. As prediabetes is not a full-
blown disease state, to date, there are no approved drugs
for its management. Lack of compliance with lifestyle in-
terventions and pharmacological agents highlights the
necessity of safe and efficacious interventions for the
management of prediabetes.
Subclinical inflammation, being the primary trigger for
many pathological mechanisms in the development of
T2D, anti-inflammatory bioactives, such as curcumin
and long-chain omega-3 polyunsaturated fatty acids
(LCn-3PUFA), appear to be an attractive strategy to
delay the risk of developing T2D in individuals with pre-
diabetes. These bioactive compounds influence multiple
numbers of physiological mechanisms and have rela-
tively higher safety profiles [22, 23]. These bioactives
could provide beneficial effects in insulin resistance and
T2D by the following pathways: (1) down-regulating in-
hibitor of kappa B kinase (IKK)/nuclear factor kappa B
(NFκB), and c-Jun N-terminal kinase (JNK) pathways for
lowering chronic low-grade inflammation, (2) scavenging
reactive oxygen species (ROS) and reducing oxidative
stress, (3) providing cytoprotection for improving beta-
cell function, (4) reducing the accumulation of fatty acid
metabolites for increasing insulin sensitivity, (5) up-
regulation of 5' AMP-activated protein kinase (AMPK),
and (6) modulating peroxisome proliferator-activated re-
ceptor gamma (PPARγ) agonistic activity.
Some preclinical studies have reported synergistic
anti-inflammatory effects of curcumin and docosahexae-
noic acid (DHA) combination. These observations sug-
gest that curcumin might provide synergistic anti-
inflammatory effects with LCn-3PUFA in the prevention
of T2D [24–26]. In this study we aim to perform a 2 × 2
factorial, double-blinded, randomised placebo-controlled
trial to evaluate the complimentary or synergistic effects
of curcumin and/or LCn-3PUFA primarily on glycaemic
profiles and in individuals with prediabetes (IFG, IGT or
both). In addition to these parameters we are also
measuring lipid profile and inflammatory parameters to
determine the effects of curcumin and/or LCn-3PUFA
on cardiovascular risk factors and chronic low-grade
inflammation.
Method/design
This is a 12-week 2 × 2 factorial, double-blinded
(study investigator and participants), randomised
placebo-controlled intervention trial for preventing
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or delaying the onset of T2D using curcumin and/or fish
oil as supplements. Eighty individuals diagnosed with pre-
diabetes (IFG fasting glucose 6.1–6.9 mmol/L; IGT-2 h
OGTT plasma glucose ≥7.8 mmol/L and ≤11.1; glycosyl-
ated haemoglobin (HbA1c) 5.7–6.5 mmol/L) aged be-
tween 30 and 70 years will be screened for enrolment at
two sites; Nutraceuticals Research Group (NRG) and John
Hunter Hospital (JHH) in Newcastle, NSW, Australia. Po-
tential participants who meet the inclusion and exclusion
criteria will be randomised to receive double placebo
(corn oil capsules or curcumin placebo tablets), curcumin
plus placebo matching for fish oil, fish oil plus placebo
matching for curcumin or both curcumin and fish oil.
Participants visit the trial sites three times at baseline
(0 weeks), interim (6 weeks) and post intervention
(12 weeks). Figure 1 shows a flow chart of the study design
and the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist is presented as
Additional file 1.
Study aims
The primary aim is to evaluate the potential of curcumin
and/or LCn-3PUFA for improvements in the HbA1c in in-
dividuals with prediabetes. Secondary outcomes include:
Fig. 1 Trial protocol flow chart
Thota et al. Trials  (2016) 17:565 Page 3 of 11
fasting plasma glucose, insulin, fructosamine, insulin
sensitivity (Homeostatic Model Assessment), lipid profile
(total cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C)), C-reactive protein (CRP), interleu-
kin (IL)-1β, IL-6, adiponectin and leptin. Erythrocyte fatty
acid composition and plasma curcumin content are mea-
sured to determine compliance with the intervention.
Inclusion criteria
To be eligible to participate in the trial, participants
should be within the age range of 30–70 years. Their
Body Mass Index (BMI) must lie between 25 and 45 kg/
m2. They must be diagnosed either with IFG (fasting
glucose 6.1–6.9 mmol/L), IGT (2-h OGTT plasma glu-
cose ≥7.8 mmol/L and <11.1 mmol/L) or both. They can
also take part in the trial if their HbA1c levels lie be-
tween 5.7 and 6.4% or they obtain a score of 12 or more
in the Australian type 2 diabetes risk (AUSDRISK) tool
assessment (a noninvasive questionnaire to determine
the risk of developing diabetes). The participants should
not take part in any clinical trial (particularly with new
investigational drugs) before starting this trial. They
must be readily available for 3 months and should be
willing to maintain similar dietary patterns and physical
activity during the trial period.
Exclusion criteria
Participants are excluded if they are unwilling to provide
blood samples during the initial and final visits. Based
on the medical questionnaire they will also be excluded
if they have established T2D, gall bladder problems,
pacemaker implants, severe neurological diseases or sei-
zures. Women who are pregnant or lactating will also be
excluded. People who consume more than two servings
of oily fish per week or take any other dietary supple-
ments known to influence blood glucose levels are also
ineligible to participate in the trial. Based on their
medication intake from the medical questionnaire, par-
ticipants will be excluded from the trial if they are taking
aspirin, warfarin, clopidogrel, ibuprofen, naproxen, dalte-
parin, enoxaparin or heparin to avoid any possible drug
interaction with curcumin.
Sample size calculation
Based on the HbA1c data of the prediabetic people from
other studies [27, 28], with a standard deviation of 0.5
units in HbA1c, a sample size of 17 participants in each
treatment group will give 80% power to detect a 0.5-unit
fall in HbA1c at a type 1 error (alpha) of 0.05. To allow
for dropouts we will recruit 4 × 20 = 80 participants
according to the inclusion criteria.
Participant recruitment
Participants will be recruited from the Hunter region in
NSW using media advertising and social media (Face-
book and Twitter) approved by the University of New-
castle Media and Marketing Department. Recruitment
flyers will be placed on notice boards at the University
of Newcastle, local pharmacies, local pathology centres
(with permission) and in newsletters. Participants will
also be recruited from the Hunter Medical Research
Institute (HMRI) Volunteer Register, as well as from
clinics across John Hunter/Newcastle Community Health
Centre and Belmont Hospital diabetes clinics, Medicare
local and GP practice databases with consent from partici-
pating GPs. Interested participants will contact the study
coordinator through email or telephone, who will screen
the participants according to inclusion and exclusion cri-
teria. Potential participants will receive a Participant Infor-
mation Sheet and the Health, Diet (3-day food record)
and Physical Activity Questionnaire (IPAQ long form)
after telephone screening. Participants will return the
completed questionnaires along with a signed Consent
Form. Study investigators will use demographic and
lifestyle details to determine participant suitability before
visiting the NRG or JHH for a baseline visit.
Baseline assessments
After returning their signed Consent Forms, participants
are provided with baseline visit details (Table 1). They
will need to complete a 3-day food record and physical
activity (IPAQ) and medical questionnaires before visit-
ing trial site. Participants will visit either NRG or JHH
after a minimum of a 10-h overnight fasting. Baseline as-
sessments include anthropometry measurements using
bioelectric impedance and a 20-mL blood sample collec-
tion for assessment of plasma glucose levels, insulin,
fructosamine, HbA1c, TC, TG, HDL-C, LDL-C, CRP,
whole blood cell count (WBC), leptin, adiponectin and
other inflammatory cytokines (IL-1β, IL-6).
Randomisation
Eligible participants who attend the baseline visit are
randomised into treatments with either double placebo,
curcumin alone, fish oil alone or double active (curcu-
min and fish oil) groups according to a computer-
generated randomisation sequence. This randomisation
is done in equal block sizes of 8 to ensure the balance
between equal numbers of men and women. Randomisa-
tion is carried out by an individual who is not involved
in trial data collection and analysis. Investigational prod-
uct will be carefully stored (under the responsibility of
the investigator) in a locked, limited-access area, safe
and separate from drugs. Only authorised persons will
have access to the storage place and capsules will be
stored in sealed HD-PE bottles at room temperature
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(15–25 °C) in a dry place, protected from light and away
from heat sources. The active and placebo capsules are
identical, encapsulated and matched for colour. To
increase the compliance of participants to the interven-
tion, they are provided with a capsule log sheet during
the study period to record their capsule intake. At the
end of the study they are advised to return the capsule
containers along with their log sheet.
Intervention
Following randomisation, participants will receive one of
the following interventions:
1. Placebo: 2 × 500-mg CN-Placebo capsules plus 2 ×
1000-mg corn oil capsules per day
2. Curcumin (Meriva curcumin): 2 × 500-mg CN
capsules (providing 180 mg curcumin/day) plus 2 ×
1000-mg corn oil capsules per day
3. LCn-3PUFA (EPAX1050): 2 × 1000-mg fish oil (FO)
capsules (providing 1.2 g eicosapentaenoic acid (EPA)/
DHA) plus 2 × 500-mg CN-Placebo capsules per day
4. Combination (curcumin and LCn-3PUFA): 2 × 500-
mg CN capsules (providing 180 mg curcumin/day)
plus 2 × 1000-mg FO capsules per day (providing
1.2 g EPA/DHA)
The participants are advised to take four capsules daily
(two with their morning meal and two with their even-
ing meal) with no changes in their dietary intake or
physical activity during the study period.
Table 1 Study timeline and trial assessments
Assessments
Screening (telephone) X
Informed consent (mail) X
IPAQ questionnaire (mail) X
3-day food record (mail) X
Medical questionnaire (mail) X
Week 1 Week 6 Week 12
Baseline (visit1) Test (visit 2) Test (visit 3)
Randomisation X
Intervention allocation X
Anthropometry measurements X X X
Blood sample X X
Food diary X X X
Physical activity X X X
Biochemical analysis X X
Fasting plasma glucose X X
Fasting plasma insulin X X
HbA1c X X
Fructosamine X X
HOMA IR, HOMA S, HOMA β, QUICKI X X
Total cholesterol X X
Triglycerides X X
HDL-C, LDL-C, Total/HDL-C ratio X X
CRP X X
Whole blood cell count X X
Il-6, Il-1β, adiponectin, leptin X X
Capsule count and log record X X
Plasma curcumin concentration X
Erythrocyte fatty acids content X X
Adverse event reporting X X
IPAQ International Physical Activity Questionnaire, HbA1c glycosylated haemoglobin, HOMA IR Homeostatic Model Assessment for Insulin Resistance, HOMA S
Insulin sensitivity, HOMA β beta-cell function, QUICKI Quantitative insulin Sensitivity Check Index, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
lipoprotein cholesterol, CRP C-reactive protein, IL-6 interleukin-6, IL-1β interleukin-1 beta
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Interim visit
Participants are scheduled for the interim visit after
6 weeks of the intervention period (Table 1). They will
need to provide completed diet and physical activity
questionnaires. Compliance for the intervention is
measured by capsule count and capsule log sheet. The
follow-up visit includes only a 10-h overnight fast and
anthropometric assessments using bioelectric impedance.
Any adverse events or reports of difficulties in compliance
with the intervention are recorded during this visit.
Post-intervention visit
The post-intervention visit is scheduled on the last day
of the participant’s intervention period (Table 1). All
baseline measures, including a 10-h overnight fast,
anthropometric measurements and blood sample collec-
tion will be repeated on this visit. They will also be asked
to fill out 3-day food record and physical activity ques-
tionnaires. Participants are advised to return capsule
containers along with the capsule log sheet on the final
visit day.
Safety and compliance monitoring
During the follow-up and post-intervention visits, any
serious adverse events (SAE), adverse events (AE) related
to intervention, compliance with intervention, or issues
with other procedures (e.g. blood collection, anthropo-
metric measurements, etc.) are discussed with partici-
pants and recorded. The study coordinator will inform
the principal investigator of all AEs and SAEs, who will
then follow procedures for unblinding as necessary and
notify the relevant bodies. Depending on the nature of
AE or SAE, it may be necessary for treatment to cease
and/or for the participant to be withdrawn from the
study. Should the need for unblinding in the curcumin
or LCn-3PUFA group versus placebo group arise, sub-
jects may inform the study coordinator or anyone from
the research team.
For emergency situations, subjects will be given an
emergency contact card, which will provide general
study information and contact information for the un-
biased randomisers. Compliance of the participant to the
intervention is measured using capsule count and cap-
sule log record. Erythrocyte fatty acid analysis is used to
measure participant compliance with fish oil. Serum
levels of curcumin are measured using HPLC; this will
be used as a measure to determine participant compli-
ance with curcumin tablets.
Ethics
This trial has been approved by the University of Newcastle
and the Hunter New England Area Health Service Human
Research Ethics Committees, Approval Nos. H-2014-
0385 and HNE HREC 16/03/16/3.02, respectively. The
trial is registered with the Australia New Zealand Clinical
Trial Registry (Trial ID ACTRN12615000559516).
Data collection and outcome measures
Primary outcome
The primary outcome measure in this trial is the differ-
ence in HbA1c levels in 12 weeks between double pla-
cebo, curcumin, LCn-3PUFA and double active groups
from baseline to the post-intervention visit (Additional
file 2). HbA1c is measured in blood samples obtained at
baseline and post-intervention visits through the cation
exchange HPLC method by Hunter New England Area
Health Pathology Services (HNEHAPS) (accredited path-
ology laboratory for compliance with National Pathology
Accreditation Advisory Council Standards).
Secondary outcomes
Secondary outcomes in this trial include glycaemic
profiles and insulin sensitivity, Lipid profile and
inflammation-related parameters (Additional file 2).
Glycaemic profiles and insulin sensitivity In addition
to primary outcome, we will also measure fasting glu-
cose and insulin levels in serum samples obtained from
the trial participants to evaluate the effects of curcumin
and/or LCn-3PUFA on glycaemic control and insulin re-
sistance between the four groups. These parameters will
be measured by HNEHAPS. Insulin resistance will be
calculated using the Homeostatic Model Assessment
equations, HOMA IR (fasting insulin (U/L) × fasting
glucose (mmol/L)/22.5). The beta-cell function will be
measured using HOMA β (20 × fasting insulin (IU/ml)/
fasting glucose (mmol/ml) − 3.5).
Lipid profile Lipid profile parameters to be measured in
this trial include TG, TC, LDL-C and HDL-C, and
TC:HDL-C ratio. These parameters will be measured in
blood samples obtained from participants at baseline
and post-intervention visits by HNEHAPS.
Inflammatory parameters Inflammation-related param-
eters, such as IL-6, IL-1β, adiponectin and leptin in
blood samples of participants at baseline and post-
intervention visits, will be measured using human
antibody-specific Enzyme-Linked Immunosorbent Assay
(ELISA) kits (R&D Systems) at our laboratory in NRG;
while the other two parameters, CRP and whole blood
cell count, will be analysed by HNEHAPS.
Additional data
Body composition
Body weight, BMI, body fat mass, percent body fat, waist-
hip ratio and skeletal muscle mass are measured using
bioelectric impedance (InBody 230). These parameters are
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measured in a fasting state at baseline, follow-up and
post-intervention visits.
Questionnaires
Changes in the dietary pattern, such as an increase in
turmeric or fatty fish intake during the trial period,
might alter the effects of intervention on clinical out-
comes. To avoid this, the participants are advised to
maintain a consistent dietary pattern during the trial
period. They will be asked to complete a 3-day food rec-
ord during each visit to enable us to get an appropriate
picture of the dietary intake pattern of participants and
identify any major changes in the dietary habits of par-
ticipants. These food diaries will be analysed with Food
Works Professional 8 2015 (Xyris software (Australia)
Pvt. Ltd.). Along with dietary intake, participants will be
advised to maintain similar physical activity during the
12-week trial period. The IPAQ long version is used to
assess the levels of physical activity. This version allows
the participants to record the number of hours or mi-
nutes that they spent on job-related physical activity,
travel-related physical activity and recreation- or sport-
related physical activity during the last 7 days. It also has
a provision for recording the number of days, hours or
minutes participant spend on walking and sitting. The
physical activity of the participant will be reported in
metabolic equivalents (METs)-minutes/week. This will
also help us to determine the impact of different levels
of physical activity on intervention.
Data analysis
Data obtained from the all participants will be ana-
lysed according to the intention-to-treat principle. In
case of missing data or dropouts, pairwise deletion will
be used to analyse the significant effect of intervention
in participants who have completed the trial. Normal-
ity of baseline data will be examined using histograms
with a normal distribution curve overlayed and the
Shapiro-Wilk test. Based on the distribution of data,
the outcome measures will be analysed using analysis
of variance (ANOVA) (normal distribution) or the
Wilcoxon signed rank test (nonparametric data). Two-
way ANOVA with post hoc comparisons (Bonferroni
correction) will be used to determine the effect of
intervention on different variables and also to
determine synergistic and/or complimentary effects
between the two interventions (curcumin and LCn-
3PUFA). ANCOVA will be used to assess the effects of
confounding factors on treatment that include age,
gender, BMI, physical activity levels and dietary intake.
Significance will be set at a P value < 0.05. Statistical
analysis will be performed using GraphPad Prism
version 6 and IBM SPSS 22 software.
Discussion
Parallel to an increase in the number of individuals with
T2D, the prevalence of people with prediabetes is also
increasing exponentially [5]. Currently, prediabetes is
managed by lifestyle modifications to delay its onset or
prevent its progression to T2D. To date there are no
pharmacological agents approved for the treatment of
prediabetes. Lifestyle modifications alone are insufficient
to bring down the prevalence of prediabetes, so there is
a need for long-term, safe and cost-effective agents that
can act through multiple mechanisms to improve insulin
sensitivity and beta-cell function. In this trial we are
evaluating the effects of the diet-derived bioactives cur-
cumin and/or LCn-3PUFA. These are derived from tur-
meric powder and seafood, respectively, and have the
potential to influence multiple mechanisms. To the best
of our knowledge, to date this is the first clinical trial de-
signed to evaluate the combination of curcumin and
LCn-3PUFA in prediabetes. If the application of curcu-
min and/or LCn-3PUFA is successful in improving insu-
lin sensitivity and glycaemic profiles in this trial, this
combination could be examined in large-scale trials that
could provide a better alternative for the management of
prediabetes to prevent or delay the onset of T2D. In
addition to the effects of curcumin and LCn-3PUFA on
glycaemic profiles, this combination might also improve
underlying chronic low-grade inflammation, which is
involved in down-regulation of insulin signalling and ac-
tivity pathways. The anti-inflammatory and triglyceride-
lowering effects of curcumin and LCn-3PUFA might also
provide an alternative option to reduce cardiovascular
risk factors in those with prediabetes, which is not seen
with conventional oral antidiabetic agents. Therefore,
this trial might be an important step in evaluating the ef-
fects of bioactives for alleviating both hyperglycaemic
and cardiovascular risk factors in individuals who are at
high risk of developing T2D.
Curcumin, an anti-inflammatory bioactive derived
from the spice turmeric has, in preclinical and in-vitro
studies, been shown to act on multiple targets for delay-
ing the risk of developing T2D; via down-regulation of
low-grade inflammation, cytoprotection of beta-cells,
improvement in beta-cell function and decreasing fat
accumulation in nonadipose tissues. Curcumin has been
shown to decrease inflammation in adipocytes via
multiple pathways such as inhibition of macrophage
infiltration, scavenging ROS and down-regulation of
proinflammatory kinase (NFκB and JKK) signalling. In-
vivo studies with curcumin supplementation in high-fat-
diet-fed genetically obese (ob/ob) mice resulted in ameli-
oration of diabetes-associated symptoms along with a
decrease in insulin resistance [29]. Multiple mechanisms,
like decreased macrophage accumulation in WAT, down-
regulation of proinflammatory cytokines and increase in
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adiponectin levels, are exhibited by curcumin for improv-
ing insulin sensitivity [29]. Curcumin increased the ex-
pression of AMPK in diabetic db/db mice, which might be
a possible mechanism in suppressing hepatic glucose pro-
duction, resulting in decreased blood glucose levels [30].
Curcumin exhibits cytoprotective mechanisms increasing
levels of key mitochondrial biogenesis-regulating tran-
scription factors like PGC-1α, nuclear respiratory factor-1
and mitochondrial transcription factor A [31]. Stimulation
of volume-regulated anion channels may be one of the
primary mechanisms for the antihyperglycaemic effects of
curcumin. Curcumin directly stimulated the volume-
regulated anion channels in rat pancreatic beta-cells. This
effect was accompanied by generation of electrical activity
and depolarisation which resulted in enhanced insulin
release [32]. Curcuminoids increased the expression of the
antioxidant enzymes heme-oxygenase 1 and NADPH:qui-
none oxidoreductase 1 at messenger ribonucleic acid
(mRNA) levels up to 12-fold and at protein levels by 6-
fold in human islets (used for human transplantation)
[33]. These observations suggest that curcumin might be
beneficial in improving cellular defense mechanisms
against oxidative stress. Direct stimulation of pancreatic
beta-cells and cellular defence against oxidative stress are
two mechanisms which provide considerable evidence for
exploring the potential of curcumin in controlling or pre-
venting T2D.
Meta-analyses and randomised controlled trials have
reported that LCn-3PUFA have either no effects or
worsening effects on glycaemic profiles and insulin sen-
sitivity [34, 35]. On the contrary, epidemiological studies
have reported an inverse correlation between regular
consumption of fish and prevalence of diabetes [36–40].
A recently published prospective study of a cohort of
407 obese and IGT participants demonstrated that ele-
vated plasma levels of LCn-3PUFA are associated with a
lower prevalence of T2D over the extended 11-year
follow-up period [41]. Elevated serum EPA, DHA and
DPA levels are associated with higher insulin sensitivity,
providing a plausible explanation for the lower preva-
lence rates of diabetes [41]. In line with epidemiological
studies, in-vitro and preclinical studies have reported
beneficial effects of LCn-3PUFA on glycaemic profiles
and insulin resistance through amelioration of chronic
low-grade inflammation and lipotoxicity. Administration
of LCn-3PUFA in the diet (5–44%) protected the high-
fat-diet-fed animals from developing lipid abnormalities
and impaired glucose homeostasis [42–44]. LCn-3PUFA
are natural agonists of PPARα subunits; the carboxylic
group and the hydrophobic chain in the structure of
LCn-3PUFA allows optimal binding to PPARα [45].
Activation of PPARα by LCn-3PUFA results in increased
fatty acid β-oxidation in peroxisomes (to a lesser extent in
mitochondria) and decreased lipogenesis. The increase in
fatty acid oxidation leads to decreased accumulation of
fatty acids (lipotoxicity) in the liver along with improve-
ment in insulin sensitivity in hepatocytes [45]. Stimulation
of AMPK by LCn-3PUFA, along with its effects on PPARα
and SREBP-1c, results in significant reduction in triglycer-
ides with overall improvement in insulin sensitivity of he-
patocytes. LCn-3PUFA, through PPARγ stimulation, has a
mechanism of action similar to that of the thiazolidine-
dione class of antidiabetic drugs [46], balances adipokine
secretion, decreases proinflammatory signalling and in-
creases insulin sensitivity [47–49]. LCn-3PUFA has been
shown in in-vitro studies to decrease diacylglycerol,
muscle ceramide and long-chain acyl CoA accumulation
in myotubes that protect high-fat-diet-fed rodents from
developing insulin resistance and improved glycogen syn-
thesis and glucose uptake in skeletal muscle [50–53]. Clin-
ical studies with supplementation of EPA +DHA at dose
of 3.1–8.4 g/day have reported a 30–55% decrease in the
production of ROS by cultured human neutrophils [54,
55]. Cell culture studies have reported EPA and DHA to
have potency to inhibit the expression of the proinflam-
matory cytokines IL-1β, tumour necrosis factor alpha
(TNFα) and NFκB by macrophages [56–58]. Recent hu-
man intervention studies with LCn-3PUFA at dose levels
between 2 and 4 g/day reported a decrease in inflamma-
tion and proinflammatory markers [59, 60]. A recently
published research study on G-protein-coupled receptors
(GPR) reported that the anti-inflammatory activity of
LCn-3PUFA is mediated through the activation of
GPR120 [61]. LCn-3PUFA stimulates GPR120 in macro-
phages and adipocytes, through which it exhibits its anti-
inflammatory mechanisms. This involves inhibition of
transforming growth factor beta (TGF-beta)-activated kin-
ase 1 (TAK 1) through a β-arrestin1/TGF-beta-activated
kinase 1/MAP3K7 binding protein 1 (TAB1)-dependent
mechanism. This inhibition leads to down-regulation in
proinflammatory pathways like IKK/NFκB and JNK/AP1
[61]. LCn-3PUFA abolishes activation of the NLRP3
inflammasome along with inhibition of caspase-1
activation and IL-1β secretion [62]. The established data
on anti-inflammatory (inhibition of inflammasome and
GPR120 activation) and triglyceride-reducing effects of
LCn-3PUFA might be an important aspect to be consid-
ered for reducing low-grade systemic inflammation, which
is a promoter for several pathological mechanisms, like
glucotoxicity and lipotoxicity, in different tissues. Regard-
less of the availability of large-volume, ambiguous clinical
data, cellular and physiological mechanisms in different
tissues still make LCn-3PUFA look like a promising agent
for delaying or reducing the risk of T2D.
The combination of curcumin and LCn-3PUFA might
provide either synergistic or complimentary effects in
prediabetes, which is evaluated through this 2 × 2 factor-
ial study design. To date previous studies have not
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reported curcumin interfering with LCn-3PUFA binding
to GPR120, thereby preventing the competitive binding
for the same receptor. Substantiating evidence of the
blood-glucose-lowering effects of curcumin and the
triglyceride-lowering effects of LCn-3PUFA might pro-
duce improved metabolic health in prediabetics. The
cytoprotective effects of curcumin might also provide
additional benefits to maintain the integrity of pancreatic
beta-cells. This trial, therefore, looks at the potential of
these two bioactives in decreasing the risk factors for de-
veloping T2D.
Strengths and limitation of study design
The strengths of this COP-D trial include valid study
methodology; factorial design to evaluate the individual ef-
fect and complimentary or synergistic effects of both in-
terventions; and double blinding of both participants and
investigators to reduce bias. The participants are advised
to maintain a constant dietary and physical activity pat-
tern, which is evaluated though questionnaires, to reduce
the effect of confounding factors on intervention. The use
of a capsule log, a capsule count, erythrocyte fatty acid es-
timation using gas chromatography and measurement of
serum curcumin levels using HPLC provides the best
measure of compliance with the interventions. No toxic
or adverse events in previous studies have been reported
at the dose of curcumin and LCn-3PUFAs used in this
trial. There might also be potential limitations for this
study because as we are measuring only risk factors like
fasting glucose and insulin, lipid parameters and proin-
flammatory cytokines, we cannot translate these results
completely into preventing or delaying the onset T2D. A
follow-up study with a larger sample size and prolonged
duration would be required to substantiate whether cur-
cumin and/or LCn-3PUFA could actually prevent or delay
the onset of T2D. If we can obtain considerable evidence
of the beneficial effects of curcumin and LCn-3PUFA this
trial can provide the basis for a safe and cost-effective ap-
proach to decrease the risk of T2D.
Trial status
Recruitment for this trial started in July 2015. This study is
currently ongoing and is actively recruiting participants
from local communities of NSW, Australia. No changes
have been made to the clinical protocol post recruitment of
participants. To date 38 participants completed all trial
visits. It is expected to take approximately 2 years (from the
starting day of trial recruitment) to complete the study.
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